XVARY Composite Score
54
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Citizens sells life and final-expense insurance to people and small businesses across 3 regions.
How it gets paid
Last year Cia made $256M in revenue.
Why it's growing
Revenue grew 254.7% last year. The $72M quarter matters because it was 14% higher than last year.
What just happened
Q4 revenue hit $72M, and EPS landed at $0.05.
At a Glance
B balance sheet — gets the job done, barely
25/100 earnings predictability — expect surprises
23.1x trailing p/e — priced about right
$0.29 fy2024 eps est
$0M fy2025 rev est
XVARY composite: 54/100 — below average
What They Do
Citizens sells life and final-expense insurance to people and small businesses across 3 regions.
Citizens sells through home service agents and funeral homes, not an app. That leaves your policy tied to a slower channel with 250 employees behind it and $1.74B in assets as of Sept. 30, 2025. For a $230M stock, that is a lot of balance sheet for a lot of old-school paperwork.
How They Make Money
$256M
annual revenue · their business grew +254.7% last year
total revenue
$256M
+254.7%
The Products That Matter
Core life insurance underwriting
Life Insurance
tied to the $255.6M revenue base
this is the core of the business. The snapshot does not break out segment revenue, but total company revenue reached $255.6M, so this line carries most of the weight.
core
Small-ticket end-of-life coverage
Final Expense Insurance
competitive niche
final expense is one of the niches management leans on, but the page gives no stand-alone premium or profit figure. That's a data gap worth noticing when the stock trades at 21.2x earnings.
watch disclosure
Living benefits insurance
Living Benefits
part of the same $255.6M pool
this broadens the offering beyond basic life policies, but again, the current snapshot does not show product-level economics. You are underwriting management's execution with limited segment detail.
thin disclosure
Key Numbers
$1.74B
assets
That is about 7.6x the $230M market cap, so the stock is priced like a sliver of the balance sheet.
$256M
revenue
That is the full-year top line, so every 1% swing is about $2.6M.
3.0%
op margin
At 3.0%, the business kept only about $7.7M from $256M of sales.
250
employees
A 250-person staff is tiny for a company with $1.74B in assets, which tells you how lean the machine is.
Financial Health
B
Strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 15 / 100
B — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
beat estimates
Q4 revenue hit $72M, and EPS landed at $0.05.
Revenue rose 14% vs. prior year. The extra sales did not turn into a huge earnings jump, which is the whole story here.
$72.0M
revenue
$0.05
eps
3.0%
op margin
the number that mattered
The $72M quarter matters because it was 14% higher than last year, while EPS stayed at $0.05.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk is a premium multiple on sub-premium economics.
High
Valuation reset
Citizens trades at 21.2x earnings versus 11.3x for the industry. If the market decides this should be priced more like its peers, you do not need a collapse in the business to get a weaker stock.
The gap between 21.2x and 11.3x is the downside setup.
High
Revenue growth without earnings growth
Full-year revenue reached a record $255.6M, up from $245.0M, yet adjusted earnings still declined from the prior year. That is a direct warning that growth is not currently flowing through cleanly to the bottom line.
If that pattern repeats, the premium multiple gets harder to defend each quarter.
Med
Thin niche advantage
The company sells in specialized insurance niches, but this snapshot does not show evidence of a moat. Competing against larger insurers without clear pricing power can keep margins stuck near the current 5.71% level.
No moat means execution has to do all the work.
Med
Short sellers are paying attention
Short interest stood at 7.62% of float as of February 27, 2026. That's not a death sentence. It is a sign that a meaningful slice of the market sees the valuation and margin profile and does not like the math.
Negative news can hit harder when skepticism is already in the stock.
A 21.2x P/E on a 5.71% net margin is manageable only if earnings start following revenue higher. If they do not, the multiple is the risk.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Metric
Net margin vs. the multiple
5.71% net margin is the cleanest reality check on a 21.2x P/E. If that margin slips, the valuation argument gets worse fast.
Calendar
Annual shareholder meeting
Management said the annual meeting should land within 120 days after December 31, 2025. Listen for how directly they address the gap between record revenue and weaker adjusted earnings.
Trend
Revenue-to-earnings conversion
Revenue grew from $245.0M to $255.6M. The next test is whether earnings finally move with it. That is the trend that matters more than another small top-line beat.
Risk
Short interest
7.62% of float sold short is not extreme, but it is enough to tell you skepticism is active. If operating results stay mixed, that camp will keep having material to work with.
Analyst Rankings
earnings predictability
25 / 100
low predictability. in human-speak, analysts do not see a clean, stable earnings story here yet.
risk rank
2
this score says the stock screens as safer than many others on the platform, even if the business still carries valuation risk.
price stability
15 / 100
the share price has not behaved like a steady compounder. You should expect bumps, not a smooth line.
Source: institutional data
Institutional Activity
institutional ownership data for CIA is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$5
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive